MNOV
MEDICINOVA INC
NASDAQ · Healthcare · Biotechnology · US
$1.42
+0.00%Year over year
Reported trailing growth
- Revenue
- +583.9%
- EBITDA
- +13.2%
- EBIT
- +10.9%
- EPS
- +9.8%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -20.9%
- EBITDA
- -66.2%
- EPS
- -70.3%
Three-year CAGR
- Revenue
- -36.0%
- EBITDA
- -8.6%
- EBIT
- -4.8%
- Net income
- -8.6%
- EPS
- -4.3%
- Free cash flow
- +7.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026